President’s Letter | January 2022
From the Desk of Samantha Guild Happy 2022! I hope this year is joyful and healthy for you and…
Blog - Melanoma360
01/27/2022
President’s Letter | January 2022
From the Desk of Samantha Guild Happy 2022! I hope this year is joyful and healthy for you and…
|
01/27/2022
In Plain English: The Results of DreamSeq
By Kim Margolin, M.D., FACP, FASCO Patients with advanced melanoma—spread to other organs or grown too large in the lymph…
|
01/26/2022
One Survivor Finds Empowerment through Education and Supporting Others
By Mara Klecker Ann Marie received her first-ever physical in 2019 at the age of 53. She’d lost her father…
|
01/26/2022
Become a Member of the Supporters Guild
“How Can I Help?” Fortunately for AIM, so many of you call or write us and ask this question. And…
|
01/26/2022
FDA Approves KIMMTRAK (tebentafusp-tebn) for the Treatment of Unresectable or Metastatic Uveal Melanoma
January 26, 2022 (Richmond, California) Earlier today, Immunocore announced that the U.S. Food and Drug Administration (FDA) has approved KIMMTRAK…
|
01/26/2022
Walking to Conquer Melanoma: Mike’s Miracle Workers
By Mara Klecker Even when the pandemic forced the KDB Melanoma 5k Walk/Run to go virtual in 2020, Mike’s Miracle…
|
|
01/26/2022
International Advocate Spotlight: Australia’s Tamara Dawson
By Mara Klecker Two-thirds of Australians will be diagnosed with a type of skin cancer by the time they are…
|
|
01/11/2022
The Role of Social Media in Patient Care
Social media has the potential to provide both benefits and harm to cancer patients who turn there looking for information…
|
12/09/2021
A Heartfelt Thank You To Our Auction Sponsors
Thank you, thank you, thank you to the donors for our 2021 online auction! The Gratitude Gala—AIM at Melanoma’s…
|
12/09/2021
President’s Letter | December 2021
From the Desk of Samantha Guild Here at AIM at Melanoma, we started 2021 talking about Hope and are ending…
|
Recent Posts
Jun. 05, 2026
Fifth Annual Evening in Memory of Valerie Guild
Jun. 05, 2026
Results for darovasertib in combination with crizotinib in first line HLA*A2:01-negative metastatic uveal melanoma met the study’s primary objective
Jun. 05, 2026
Encouraging results with anzutresgene autoleucel in patients with uveal melanoma and other melanoma subtypes
Jun. 05, 2026
Promising early results with imneskibart, low-dose subcutaneous IL-2, and nivolumab in patients who do not respond to or who relapse after receiving combination checkpoint inhibitors
Jun. 05, 2026